What is CRISPR Cas9?

CRISPR Cas9 system is recently considered as the most remarkable breakthrough in genome editing technology. Compared with the existing TALEN and ZFN, the CRISPR Cas9 system can provide more precise DNA modification through the RNA-directed Cas9 nucleases. Previous studies have indicated that the on-target gene knockout rate is higher than that of TALEN and ZFN, and the CRISPR Cas9 system is more efficient and economical. CRISPR/Cas9, the most promising gene editing tool, has been widely applied to animal and plant breeding, directed evolution, and the site-specific restoration of genetic diseases.

What are the Advantages of CRISPR-Cas9?

  • Simple Construction: The system based on the Cas9 nuclease and an engineered sgRNA that specifies a target nucleic acid sequences.
  • An Efficient Tool for Genome Editing: The plasmid of sgRNA and Cas9 is easy to construct and utilize.
  • Multiple Functions of CRISPR-Cas9: Gene KO/KI, Genome-scale Screening (sgRNA library), CRISPRi, CRISPRa.
  • Widely applications: The CRISPR-Cas9 system can be applied to different species, including mammals, plants and microorganisms.

CRISPR Cas9 applications

CRISPR Cas9 Services

CRISPR Cas9 sgRNA Design Center

CRISPR Cas9 sgRNA Library Design and Screening

Yeast Genome Editing

Mammalian Cell Line Gene Editing

CRISPR Cas9 sgRNA Panel

sgRNA Bioinformatics Service


1.Shalem O, Sanjana N E, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 2014, 343(6166): 84-87.
2.Cong L, Ran F A, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science, 2013, 339(6121): 819-823.
2.Hsu P D, Lander E S, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell, 2014, 157(6): 1262-1278.
3.Yang L, Güell M, Niu D, et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science, 2015, 350(6264): 1101-1104.
4.Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & cell, 2015, 6: 363-372.